<DOC>
	<DOCNO>NCT02172807</DOCNO>
	<brief_summary>Study investigate efficacy safety Ba679BR powder inhalation continuous once/day administration patient COPD use oxitropium bromide ( Tersigan® aerosol ) comparator drug .</brief_summary>
	<brief_title>Efficacy Safety Ba679BR Powder Inhalation Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Oxitropium</mesh_term>
	<criteria>Diagnosis COPD ( chronic bronchitis , emphysema ) stable symptom : Screening FEV1.0 ≤70 % predict normal vale screen FEV1.0/FVC ≤70 % ( baseline FEV1.0 also ≤70 % predict normal value initial day administration ) Smoking history ≥ 10 packyears ( peakyear 20 cigarette per day one year equivalent ) Male female patient 40 year age old History bronchial asthma History atopic disease allergic rhinitis Total blood eosinophil count ≥ 600/µL Patient treat antiallergic drug antihistamine drug Patients use oral corticosteroid medication unstable dos ( i.e . le one month stable dose ) dose excess equivalent 10 mg prednisolone per day Patients use inhaled steroid , oral β2 stimulant , theophylline preparation , expectorant macrolide antibiotic unstable dos ( i.e . le one month stable dose ) Patients use ACE inhibitor unstable dos ( i.e . le one month stable dose ) Patients known narrowangle glaucoma Patients know symptomatic prostatic hypertrophy Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system Patients significant disease opinion investigator eligible study Patients clinically significant abnormal baseline laboratory test value ( hematology , blood chemistry , urinalysis ) . Patients serum glutamicoxaloacetic transaminase ( SGOT ) serum glutamicpyruvic transaminase ( SGPT ) twice upper limit normal range , bilirubin 150 % creatinine 125 % upper limit normal range exclude Patients recent history ( i.e . within 3 month prior screen visit ) myocardial infarction heart failure Patients cardiac arrhythmia require drug therapy Patients treat Patients treat βblockersblockers Patients regular use daytime oxygen therapy Patients know active tuberculosis obvious sequela tuberculosis Patients history cancer within last 5 year . Patients treat basal cell carcinoma allow Patients history cystic fibrosis bronchiectasis Patients upper respiratory tract infection past one month prior screen visit baseline period Patients take investigational drug within one month six half life ( whichever great ) prior screen visit Pregnant nursing woman woman childbearing potential Other , patient opinion investigator eligible study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>